193 related articles for article (PubMed ID: 37621724)
1. Management of PALB2-associated breast cancer: A literature review and case report.
Toss A; Ponzoni O; Riccò B; Piombino C; Moscetti L; Combi F; Palma E; Papi S; Tenedini E; Tazzioli G; Dominici M; Cortesi L
Clin Case Rep; 2023 Aug; 11(8):e7747. PubMed ID: 37621724
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
3. PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
Gonzalez A; Del Greco F; Vargas-Roig L; Brun B; Tabares G; Mampel A; Montes C; Martin C; Lopez M; Rossi N; Bruno L; Ponce C; Quaglio P; Yanzi A; Acevedo S; Lugo L; Lopez Breccia P; Avila S; Sisterna S; Del Castillo MS; Vazquez M; Nuñez LM
Breast Cancer Res Treat; 2022 Jul; 194(2):403-412. PubMed ID: 35610400
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
Landry I; Sumbly V; Vest M
Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing surgery in
Masanam MK; Pitcher CW; Sogunro O; Starks LK; Murray AB; Boisvert ME
Transl Breast Cancer Res; 2022; 3():37. PubMed ID: 38751533
[TBL] [Abstract][Full Text] [Related]
7. BRCA2, PALB2, RECQL4 Germline Pathogenic Variants, and Somatic TP53 Mutation in Triple Metachronous Malignancies: A Case Report and Literature Review.
Liu Y; Yang H; Fu X; Zhong L; Xu P; Fang F; Liu Y; Li Q; Yan Y; Wei S; Wang J; Zhang C
Int Med Case Rep J; 2024; 17():23-29. PubMed ID: 38223534
[TBL] [Abstract][Full Text] [Related]
8. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
; Mavaddat N; Dorling L; Carvalho S; Allen J; González-Neira A; Keeman R; Bolla MK; Dennis J; Wang Q; Ahearn TU; Andrulis IL; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Briceno I; Brüning T; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Christiansen H; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; Geisler J; Giles GG; Guénel P; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Hartikainen JM; Hartman M; Hoppe R; Howell A; Jakubowska A; Jung A; Khusnutdinova EK; Kristensen VN; Li J; Lim SH; Lindblom A; Loizidou MA; Lophatananon A; Lubinski J; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Morra A; Muir K; Obi N; Osorio A; Park-Simon TW; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Thorne H; Tomlinson I; Torres D; Truong T; Yip CH; Spurdle AB; Vreeswijk MPG; Dunning AM; García-Closas M; Pharoah PDP; Kvist A; Muranen TA; Nevanlinna H; Teo SH; Devilee P; Schmidt MK; Easton DF
JAMA Oncol; 2022 Mar; 8(3):e216744. PubMed ID: 35084436
[TBL] [Abstract][Full Text] [Related]
9. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
11. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
13. PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients.
Siraj AK; Bu R; Parvathareddy SK; Iqbal K; Azam S; Qadri Z; Al-Rasheed M; Haqawi W; Diaz M; Victoria IG; Al-Badawi IA; Tulbah A; Al-Dayel F; Ajarim D; Al-Kuraya KS
Sci Rep; 2023 May; 13(1):7666. PubMed ID: 37169825
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.
Janssen B; Bellis S; Koller T; Tischkowitz M; Liau SS
J Hum Genet; 2020 Jan; 65(2):199-205. PubMed ID: 31619740
[TBL] [Abstract][Full Text] [Related]
16. Functional Characterization of
Boonen RACM; Vreeswijk MPG; van Attikum H
Front Mol Biosci; 2020; 7():169. PubMed ID: 33195396
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
18. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
19. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
20. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
